Tavilermide

Tavilermide
Systematic (IUPAC) name
	3-[(5S,8S,11S)-8-(4-aminobutyl)-5-(carboxymethylcarbamoyl)-16-nitro-7,10,13-trioxo-2-oxa-6,9,12-triazabicyclo[12.4.0]octadeca-1(14),15,17-trien-11-yl]propanoic acid
Clinical data
Routes of; administration	Eye drop
Identifiers
CAS Number	263251-78-1
ATC code	None
PubChem	CID: 9808372
ChemSpider	7984131
Chemical data
Formula	C24H32N6O11
Molecular mass	580.54448 g/mol
	SMILES C1COC2=C(C=C(C=C2)[N+](=O)[O-])C(=O)NC(C(=O)NC(C(=O)NC1C(=O)NCC(=O)O)CCCCN)CCC(=O)O ;
	InChI InChI=1S/C24H32N6O11/c25-9-2-1-3-15-23(37)29-17(22(36)26-12-20(33)34)8-10-41-18-6-4-13(30(39)40)11-14(18)21(35)27-16(24(38)28-15)5-7-19(31)32/h4,6,11,15-17H,1-3,5,7-10,12,25H2,(H,26,36)(H,27,35)(H,28,38)(H,29,37)(H,31,32)(H,33,34)/t15-,16-,17-/m0/s1 ; Key:DVJXNXPFYJIACK-ULQDDVLXSA-N ;

Tavilermide (INN) (developmental code name MIM-D3) is a selective, small-molecule partial agonist of TrkA, or a nerve growth factor (NGF) mimetic.^[1]^[2]^[3] It was under development by Mimetogen Pharmaceuticals as an ophthalmic (eye drop) solution for the treatment of dry eyes, and reached phase III clinical trials for this indication. Tavilermide is currently being evaluated in two multi-center Phase 3 clinical studies in the United States for the treatment of dry eye disease.[1] Tavilermide is also in phase I clinical trials for the treatment of glaucoma; studies are ongoing.^[4][2]

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

Systematic (IUPAC) name

3-[(5S,8S,11S)-8-(4-aminobutyl)-5-(carboxymethylcarbamoyl)-16-nitro-7,10,13-trioxo-2-oxa-6,9,12-triazabicyclo[12.4.0]octadeca-1(14),15,17-trien-11-yl]propanoic acid
Clinical data
Routes of administration	Eye drop
Identifiers
CAS Number	263251-78-1
ATC code	None
PubChem	CID: 9808372
ChemSpider	7984131
Chemical data
Formula	C₂₄H₃₂N₆O₁₁
Molecular mass	580.54448 g/mol
SMILES C1COC2=C(C=C(C=C2)[N+](=O)[O-])C(=O)NC(C(=O)NC(C(=O)NC1C(=O)NCC(=O)O)CCCCN)CCC(=O)O
InChI InChI=1S/C24H32N6O11/c25-9-2-1-3-15-23(37)29-17(22(36)26-12-20(33)34)8-10-41-18-6-4-13(30(39)40)11-14(18)21(35)27-16(24(38)28-15)5-7-19(31)32/h4,6,11,15-17H,1-3,5,7-10,12,25H2,(H,26,36)(H,27,35)(H,28,38)(H,29,37)(H,31,32)(H,33,34)/t15-,16-,17-/m0/s1 Key:DVJXNXPFYJIACK-ULQDDVLXSA-N